Many patients relapse after taking lamivudine discontinuation, so what are the principles of treatment for relapse after lamivudine discontinuation? The following is an analysis for you: (1) early detection and early treatment After discontinuation of the drug, we should check HBV-DNA or liver function once a month, find abnormalities and deal with them in a timely manner, and increase the medication to prevent the development of aggravation of the disease. As soon as the HBV-DNA turns positive, treatment should be urgently sought, do not wait for liver function to be significantly abnormal before treatment. (2) Combined antiviral High-dose bitter ginseng and thymidine. If the disease is acute, reapply lamivudine or apply entecavir and adefovir. For ALT over 500U/L, total bilirubin over 100umol/L, or bilirubin rising more than 20umol/L daily despite treatment, liver-protective treatment measures must be intensified. (3)Use hepatoprotective drugs such as hepatocyte growth stimulant 160mg or twice a day, glycine 40-50ml intravenous drip, or hepatic stimulant and hepatic hydrolytic peptide together, or add hepatogens, calf blood de-protein, etc., intravenous drip, fresh human plasma, albumin, etc. for patients with severe disease. (4) Contraindications Drugs with uncertain efficacy, stimulating to hepatocytes or aggravating the detoxification burden of the liver are prohibited, and the use of Chinese medicinal preparations in large quantities is generally not recommended for seriously ill patients. (5) Application of adrenocorticosteroids For patients with ALT and AST not very high, but heavy biliousness can be considered the application of adrenocorticosteroids, we advocate that oral administration is preferable, generally apply dexamethasone 0.75mg, 3 times daily, orally, or prednisone 10m8, 3 times daily, note that those with gastric fundic varices are prohibited prednisone, after 3-7 days of application depending on the condition The dose should be gradually reduced after 3-7 days of application. When reducing the dose, still use the original dose orally, but reduce the number of doses, from 3 times to 2 times per mouth, and after 1 week Ran reduced to 1 time, and then 1 week reduced to 1 time every other day. Adrenocorticotropic hormone has a positive effect on reducing the patient’s reactivity to HBV and relieving inflammation; however, the timing and dose of the drug should still be carefully controlled, and those whose condition can be controlled should not be used as much as possible.